The Flaw Behind Everything Wrong With US Healthcare
Pioneers
Zach Reitano
Summary
- Healthcare can deserve a much larger share of GDP if spending buys more healthy years. Reitano rejects treating America’s 18% share as inherently excessive: in a world of abundance, “another healthy year” has no declining marginal return. His distinction is between a market expanding because care becomes cheaper and more useful, and spending rising because each service costs more.
- Reitano’s structural diagnosis is that “the patient is not the client.” Whoever controls payment shapes the system, while patients bear costs through taxes, lower wages, and direct spending. He sees cash-pay GLP-1 distribution as evidence that removing intermediaries can simultaneously lower consumer prices, expose pricing, and increase manufacturers’ profits through volume.
- Ro’s position rests on years of infrastructure investment and a willingness to leave substantial economics with drugmakers. Its integrated medical records, laboratories, pharmacies, and clinical network preceded GLP-1s by four to five years. Reitano accepts that inventors should capture more margin than distributors; his Costco comparison combines modest product margins with membership economics, while “constant innovation” supplies differentiation.
- Reitano signals that a majority of Americans could eventually use GLP-1 drugs, but gives no explicit ten-year percentage forecast. His adoption argument extends beyond weight loss to the “slow clock” of chronic disease, with existing indications and research across additional conditions expanding the potential market. Accessibility remains a major question, and he assumes tolerability and understanding of the drugs will improve.
- Ro’s turnaround began when Reitano recognized a well-funded “zombie company.” After raising $500 million at a $5 billion valuation, Ro grew only 9% in 2021; he describes roughly $800 million of debt and a loss of cultural clarity. The subsequent reset helped take annual revenue from approximately $250 million to more than $3 billion over four years, with headcount falling from roughly 600 to just over 400.
- Reitano credits concentrated, sequential execution with converting the GLP-1 wave into operating leverage. Ro emphasized its strongest employees, held daily leadership meetings for two years, and reduced competing priorities. He favors “long-term uncertainty” with “short-term accuracy and rigor,” arguing that detailed roadmaps create false precision when treatments, regulation, and AI change quickly.
- Ro’s next ambition combines digital biology, AI, and new treatments to broaden access to personalized care. Reitano imagines continuous interpretation of genetics, laboratory results, wearables, and patient reports, ultimately at “the price of a Netflix subscription.” His prevention framework follows lifetime exposure—the “area under the curve”—rather than an employer’s shorter coverage horizon.
- Ro treats stigma as demand that patients need permission to express. Serena Williams’ account of needing treatment despite disciplined exercise and diet illustrates the role of “permission structures.” Reitano argues that authentic celebrity stories become more valuable as AI makes polished advertising cheap, while recurring criticism of maintenance medication reveals unresolved attitudes toward obesity.
Deep dive
1. Healthcare’s GDP share measures spending, not success
- O’Shaughnessy asks what share of GDP healthcare should occupy in 10–15 years; Reitano answers, “as high as possible.” In an AI-driven world of abundance, he argues, “another healthy year” is the one good without declining marginal returns. The relevant question is what spending delivers, rather than whether 18% of GDP is intrinsically excessive.
- His Jevons-paradox distinction: cheaper units should expand consumption and the overall market. America’s problem is rising unit costs, with probably half of healthcare spending going to 5% of people. He sees America as a preview: healthcare’s GDP share rose from 6% to 12% in Britain, 9% to 12% in Germany, and 9% to 18% in America.
- Reitano defends American emergency care, citing stronger survival after cancer, heart attacks, and strokes, while saying utilization is no higher than in other OECD countries. Hospitalizations and stays are lower; prices and administrative burdens are higher. His spending map puts 30–35% in hospital systems, 20–25% in physicians’ offices, and 9–10% in medicines.
- He separates the “fast clock” of firearms, crashes, and overdoses from the “slow clock” of chronic disease. Both affect life expectancy, but chronic illness accounts for most deaths; stagnant longevity therefore cannot simply be read as a verdict on medical treatment.
2. Payment control determines whom healthcare serves
- Reitano’s central claim is that “the patient is not the client”: the client controls money at purchase. Patients finance healthcare through taxes and forgone wages without directing most transactions. Employers care about groups over employment-length horizons; individuals care about themselves and their families over lifetimes. That mismatch produces decisions poorly aligned with personal goals.
- His counterexamples are cash-pay markets such as laser vision correction and cosmetic surgery, where he sees falling costs and improving quality and convenience. GLP-1s expose the difference between a $1,300 list price and $300–$400 net receipts. Direct distribution can eliminate that gap; he cites cash prices reaching $149 while manufacturers earn more through increased volume.
- Calling PBMs an “appendix,” he argues software can replace their remaining functions. His proposed alternative gives employees a restricted medical spending account—say $20,000, with balances carried forward—plus emergency insurance. Patients could then choose providers and demand visible prices. Businesses would disclose prices to win customers, rather than requiring regulators to force transparency.
3. Ro’s distribution advantage was built before GLP-1s
- Ro operates across cardiometabolic health, sexual health, dermatology, and reproductive health. Cardiometabolic care is its largest category, with GLP-1s the fastest-growing business. Reitano calls Ro the country’s leading GLP-1 provider, estimating that it enrolls probably two to five times as many patients daily as competitors.
- The platform required four to five years of preparation: proprietary electronic medical records, a CLIA-certified and CAP-accredited laboratory, pharmacies, pharmacy software, and a provider network. Reitano wants Ro understood as an integrated care platform, rather than a collection of condition-specific storefronts. That preparation allowed rapid expansion when GLP-1 demand arrived.
- Practical advantages include integrations with Novo and Lilly, cash payment and insurance navigation, home delivery or pickup, and multi-month offers saving $600–$1,800 annually. He says AI has helped more than 1% of Americans check insurance coverage free. For many customers, those savings cover membership; nevertheless, he insists the durable differentiator is “constant innovation.”
- O’Shaughnessy’s pushback: with relatively few drug suppliers, shouldn’t manufacturers capture most margins? Reitano agrees—and thinks they should. Costco is his analogy: perhaps 15% product margins, substantial membership gross profit, and a scalable business valuable to suppliers and customers. He accepts the demand-aggregator framing while acknowledging that serving another patient is not free.
4. GLP-1 adoption could extend far beyond weight loss
- Reitano describes indications expanding from diabetes into obesity, cardiovascular disease, sleep apnea, and liver and kidney disease. He distinguishes those uses from ongoing research into neurodegeneration, pain, addiction, mental health, and cancer prevention. What sounds like a narrow weight-loss business is, in his framing, treatment of underlying causes of death.
- O’Shaughnessy raises the possibility that more than 50% of Americans could use GLP-1s in ten years. Reitano responds affirmatively to the prospect of widespread use, citing 75% of the U.S. population being overweight or obese and only 10–12% being metabolically healthy, but he gives no explicit numerical forecast. Some people should not take them or cannot tolerate them; accessibility remains a substantial question, alongside improving tolerability.
- Statins, taken by 40–50 million people, are his adoption comparison, although he considers GLP-1s broader in effect. He also claims GLP-1 revenue exceeds AI revenue and that twice as many people pay for GLP-1s as for AI—a contrast he uses to question AI’s current everyday consumer impact.
- His larger argument is that “health is a prerequisite for progress.” He links reductions in infectious disease and child and maternal mortality to greater investment in children, education, and women’s participation in work. Tackling chronic disease earlier could similarly reshape society, though he says the resulting changes are impossible to predict.
5. Outcomes should outrank preserving existing jobs
- Reitano objects to making medicine’s continued humanness the objective: people and technologies should both prove their effectiveness. His analogy is roughly 40,000 annual road deaths, comparable to breast-cancer deaths. Where autonomous vehicles demonstrate safety 10–20 times better than human drivers in particular conditions, he argues, deployment should be evaluated primarily through lives saved.
- He retells an unnamed autonomous-driving CEO’s encounter with a regulator worried that fewer fatal crashes would reduce donor organs. The CEO’s response, as related to Reitano: organs should remain with their original owners. New technology must demonstrate substantially better outcomes, he stresses, but existing methods should face scrutiny too. Job losses matter; they should not outrank lives.
6. Ro’s refounding began with an uncomfortable diagnosis
- In January 2021, Ro raised $500 million at a $5 billion valuation. By December, reviewing results on a flight, Reitano saw only 9% annual growth and what he describes as about $800 million of debt. The company had confused its long-term vision with near-term strategy, hiring broadly and attempting everything simultaneously. His diagnosis was a “zombie company.”
- A Slack complaint about plastic packaging around employee gifts crystallized his frustration. Initially angry at the employee, he became angrier at himself: the organization had become “soft.” He wrote his co-founders a six-page memo affirming the mission, technology, and people while demanding a clearer culture and decisive changes beginning in 2022.
- The reset removed about seven vice presidents and 20% of staff; another 6–7% later chose to leave. Reitano calls layoffs “the worst part of the job” and rejects celebrating them. Headcount moved from roughly 600 to just over 400 while the business grew about tenfold; annual revenue rose from approximately $250 million to more than $3 billion over four years.
- The desired culture combines maximum performance with a big heart, explicitly including “work hard.” His restaurant analogy distinguishes preferences from execution failures: a vegan should avoid a steakhouse, but an overcooked steak is a legitimate complaint. Ro’s founders had failed to show people the menu before hiring them; he takes responsibility for that ambiguity.
7. Sequential work lets results compound
- Reitano credits investment in top performers through compensation, promotions, coaching, and resources, alongside relentless focus. Building five things simultaneously creates visible progress everywhere but can prevent any one from becoming consequential. His analogy is repeatedly experiencing only the first ten years of a compounding curve and never reaching year 30. Sequential projects can build on completed predecessors.
- Beginning around December 2022, Ro’s leadership met every morning for two years. Meetings lasted whatever decisions required—from minutes to an hour and a half. A commitment made Monday became difficult to leave untouched Tuesday and Wednesday; weekly meetings allowed distractions and ambiguous priorities to accumulate. Ro still uses this cadence when particular initiatives need acceleration.
- He rejects elaborate long-term roadmaps in fast-changing GLP-1 and AI markets, comparing them to printing road maps instead of using Google Maps. This is not permission to abandon rigor or all planning beyond six months. His preferred combination is “long-term uncertainty” and “short-term accuracy and rigor”: maintain a stable mission, then update implementation as evidence arrives.
8. Three forces could make personalized care broadly accessible
- Reitano identifies three tailwinds: biology becoming digital through symptoms, laboratories, genetics, and wearables; work once requiring a specialist now requiring a prompt; and treatments materially changing quality and length of life. His provocative comparison is investors paying $100,000 annually for a personal doctor while paying $20 monthly for Claude. He also emphasizes telemedicine’s appeal to exhausted physicians.
- Ro’s scale creates questions about why outcomes differ by sex, ethnicity, and individual response—why one patient loses 35% of body weight and another 5%. Combining genetics, continuous testing, wearables, and patient reports might detect disease’s “whisper” earlier. Reitano’s ambition goes beyond moving personalized care online: a new form of healthcare at “the price of a Netflix subscription.”
9. Prevention follows lifetime exposure rather than coverage windows
- Asked to sell O’Shaughnessy on GLP-1s, Reitano instead starts with goals, family history, and individual risk-benefit assessment with a clinician. Healthcare evaluates risk over 10–15 years; he worries about ages 55, 65, and 75. Chronic disease is an “area under the curve” problem: how long LDL remains elevated or metabolic dysfunction persists matters.
- His father’s first heart attack and stroke occurred at 39. Around 30, Reitano had cholesterol of 230, apoB above 100, and LDL of 130–140 despite diet and exercise. Working with his father, he added statins, Zetia, Repatha, and later GLP-1 treatment. He describes LDL declining through 70–80 and 60 to 10, with drugs and doses tested individually.
- O’Shaughnessy, who takes Repatha despite no family history, presses for the benefits and trade-offs of lowering LDL so aggressively. Reitano answers through favorable personal tolerability, several hundred dollars of monthly expense, and the asymmetric consequences of heart attack or stroke, without estimating years gained. He cites Repatha’s direct-sale price falling from $600 monthly to $200.
- His PCSK9 example traces the 2000 Dallas Heart Study to a 2006 finding: people with a defective gene had LDL of 30–40 and 85–90% lower heart-disease risk. Amgen’s Repatha followed in 2015; he says Merck received approval for an oral peptide in 2026. His complaint is the six years to identify the signal and roughly quarter-century to an oral treatment—delays AI could help shorten.
10. Consumer demand starts with wants and permission
- Ro’s ED beachhead began with what patients wanted, then found the intersection with what they needed. Starting with “want” forces clinicians to ask rather than assume. Disrupting care nevertheless requires evidence: Ro publishes outcomes and side-effect-response data. Its AI classifies messages, converts side effects into assigned clinical tasks with deadlines, and, he says, produces responses within 30 minutes, 24/7.
- O’Shaughnessy asks whether stigma signals unmet demand. Reitano’s example is a subway campaign showing clinically eligible patients alongside “weekly injection for weight loss.” The controversy exposed beliefs that obesity reflected insufficient willpower and medication was an easy escape. He wants Ro to challenge those beliefs while remaining confident history will support the patient benefit.
- Celebrity campaigns create “permission structures.” Reitano recounts a patient reassured that Serena Williams needed treatment despite diet and exercise after having children. He credits his co-founder with building campaigns around authentic experiences, including Charles Barkley and Chrissy Metz. As AI reduces the cost of polished advertising, recognizable people and credible personal stories become more useful for breaking through.
- Reitano sees stigma in asking when patients can stop weight-loss medication: cholesterol rises when cholesterol treatment stops, and exercise requires repetition too. Patients should be free to stop safely and without judgment; ongoing treatment should not itself be scandalous. His next area of interest is earlier prevention, contrasting suspicion of studied medicines with society’s acceptance of alcohol.
11. The mission is to scale a father’s care
- Reitano wants to reproduce his father’s care through software, operations, and technology: a physician’s reach is bounded by people he can personally help; software can reach millions. His wife Cleo’s Huge If True expresses a parallel ambition: “when people see a better future, they help build it.” Both missions became clearer retrospectively.
- He pushes back on founder worship by crediting his support network. He and Cleo have been together for 13 years and took turns supporting one another financially. When Ro began, her journalism salary paid for their meals while they shared a friend’s apartment. His achievement, he argues, cannot sensibly be attributed to one person.
- His closing story explains the “big heart.” Visiting him at boarding school when he was 15, his father was suffering a fourth heart attack but paused to ask, “Tell me you love me.” He feared dying with an argument as their final exchange. He survived; Reitano took away the habit of expressing love explicitly, including to his co-founder.